- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
21 result(s) found for: Immunofluorescence Microscopy.
Displaying page 1 of 2.
EudraCT Number: 2016-002790-35 | Sponsor Protocol Number: C12-48 | Start Date*: 2019-02-07 | |||||||||||
Sponsor Name:INSERM | |||||||||||||
Full Title: Phase I/II ex vivo gene therapy clinical trial for RDEB using autologous skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector | |||||||||||||
Medical condition: The trial aims to treat the recessive dystrophic epidermolysis bullosa (RDEB) by grafting one to three subjects with RDEB with autologous COL7A1-modified skin equivalents, using SIN-RV encoding COL... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002391-14 | Sponsor Protocol Number: SAWV1003 | Start Date*: 2005-09-29 |
Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust | ||
Full Title: Pulsed Intravenous Methylprednisolone for Ocular Pemphigoid- A Pilot Study | ||
Medical condition: ocular mucous membrane pemphigoid | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-003610-15 | Sponsor Protocol Number: RITUXVAS | Start Date*: 2005-12-15 |
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | ||
Full Title: An international, randomised, open trial comparing a rituximab based regimen with a standard cyclophosphamide/azathioprine regimen in the treatment of 'generalised' ANCA associated vasculitis. | ||
Medical condition: Anti neutophil cytoplasmic antibody (ANCA) associated vasculitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) CZ (Completed) SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-005141-23 | Sponsor Protocol Number: 021FSGS16010 | Start Date*: 2018-09-18 | |||||||||||
Sponsor Name:Retrophin, Inc. | |||||||||||||
Full Title: A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with... | |||||||||||||
Medical condition: Focal segmental glomerulosclerosis (FSGS) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) CZ (Ongoing) ES (Ongoing) PL (Ongoing) HU (Prematurely Ended) DK (Ongoing) EE (Ongoing) SE (Ongoing) PT (Ongoing) BE (Ongoing) HR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004884-19 | Sponsor Protocol Number: LENTICOL-F | Start Date*: 2016-05-24 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: Phase I study of lentiviral-mediated COL7A1 gene-modified autologous fibroblasts in adults with recessive dystrophic epidermolysis bullosa (RDEB) | |||||||||||||
Medical condition: Recessive Dystrophic Epidermolysis Bullosa | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004806-17 | Sponsor Protocol Number: PQ-313-002 | Start Date*: 2018-05-18 | |||||||||||
Sponsor Name:Wings Therapeutics Inc. | |||||||||||||
Full Title: A first in human, double-blind, randomized, intra-subject placebo-controlled, multiple dose study of QR-313 evaluating safety, proof of mechanism, preliminary efficacy and systemic exposure in subj... | |||||||||||||
Medical condition: Recessive Dystrophic Epidermolysis Bullosa (RDEB) due to mutation(s) in exon 73 of the COL7A1 gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) DE (Prematurely Ended) CZ (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000713-32 | Sponsor Protocol Number: CAEL101-302 | Start Date*: 2020-12-23 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dysc... | |||||||||||||
Medical condition: stage IIIa cardiac AL amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) GR (Ongoing) PL (Ongoing) BE (Completed) AT (Ongoing) CZ (Ongoing) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003437-15 | Sponsor Protocol Number: P170922J | Start Date*: 2019-04-03 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | |||||||||||||
Full Title: Rituximab from the FIRst Episode of Idiopathic Nephrotic Syndrome | |||||||||||||
Medical condition: Minimal Change Nephrotic Syndrome (MCNS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002936-55 | Sponsor Protocol Number: MSC-EB_2020 | Start Date*: 2021-08-11 |
Sponsor Name:Masarykova univerzita | ||
Full Title: Safety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells in Patients with Epidermolysis Bullosa: Clinical Trial Phase I/II | ||
Medical condition: Epidermolysis bullosa congenita | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: CZ (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000605-72 | Sponsor Protocol Number: CB+MSCforEB | Start Date*: 2014-02-06 |
Sponsor Name:Universitair Medisch Centrum Utrecht | ||
Full Title: Unrelated cord blood transplantation after reduced toxicity conditioning with mesenchymal stromal cell co-infusion in patients with severe epidermolysis bullosa | ||
Medical condition: The source population consists of patients referred to or within the UMC Groningen because they have diagnosed clinically and genetically severe generalized RDEB. | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004254-28 | Sponsor Protocol Number: CAEL101-301 | Start Date*: 2021-01-07 | |||||||||||
Sponsor Name:Caelum Biosciences, Inc. | |||||||||||||
Full Title: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dysc... | |||||||||||||
Medical condition: stage IIIb cardiac AL amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Ongoing) GB (GB - no longer in EU/EEA) GR (Ongoing) PL (Ongoing) BE (Trial now transitioned) AT (Ongoing) CZ (Trial now transitioned) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001821-42 | Sponsor Protocol Number: CL011_168 | Start Date*: 2018-08-02 | |||||||||||
Sponsor Name:ChemoCentryx, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy | |||||||||||||
Medical condition: C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, fo... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) NL (Completed) ES (Completed) DK (Completed) FR (Completed) IT (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003682-34 | Sponsor Protocol Number: VKTX01 | Start Date*: 2019-10-23 |
Sponsor Name:Vitaeris Inc. | ||
Full Title: A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients | ||
Medical condition: Chronic Active Antibody-Mediated Rejection (CABMR) in Kidney Transplant Recipients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) HU (Prematurely Ended) BE (Completed) DE (Temporarily Halted) NL (Completed) AT (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004664-58 | Sponsor Protocol Number: BESTCILIA-WP5 | Start Date*: 2014-08-26 | |||||||||||
Sponsor Name:Paediatric Pulmonary Service, Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark | |||||||||||||
Full Title: RANDOMIZED CONTROLLED TRIAL (RCT) TO DETERMINE THE EFFICACY AND SAFETY OF AZITHROMYCIN (AZN) MAINTENANCE THERAPY FOR 6 MONTHS IN SUBJECTS WITH PCD - A DOUBLE-BLIND, PARALLEL GROUP STUDY | |||||||||||||
Medical condition: Primary ciliary dyskinesia (PCD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000606-37 | Sponsor Protocol Number: MesenSistem-EB | Start Date*: 2017-11-16 |
Sponsor Name:Fundación para la Investigación Biomédica Hospital Universitario La Paz | ||
Full Title: Safety and preliminary efficacy study of infusing mesenchymal stem cells derived from bone marrow for treating Recessive Dystrophic Epidermolysis Bullosa. | ||
Medical condition: Recessive Dystrophic Epidermolysis Bullosa | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003835-31 | Sponsor Protocol Number: IB2018-04 | Start Date*: 2021-09-28 | |||||||||||
Sponsor Name:Institut Bergonié | |||||||||||||
Full Title: Targeting ATR in soft-tissue sarcomas: a randomized phase II study. TARSARC study | |||||||||||||
Medical condition: Locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004174-64 | Sponsor Protocol Number: DMX-200-301 | Start Date*: 2022-03-08 | ||||||||||||||||
Sponsor Name:Dimerix Bioscience Pty Ltd | ||||||||||||||||||
Full Title: A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving... | ||||||||||||||||||
Medical condition: Focal segmental glomerulosclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000382-41 | Sponsor Protocol Number: WA29330 | Start Date*: 2015-03-06 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A randomized, double-blind, double-dummy active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris | |||||||||||||
Medical condition: Pemphigus Vulgaris (PV) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003564-37 | Sponsor Protocol Number: PRN1008-005 | Start Date*: 2016-04-21 | |||||||||||
Sponsor Name:Principia Biopharma Australia Pty Ltd | |||||||||||||
Full Title: An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment with the BTK Inhibitor PRN1008 in Patients with Newly Diagn... | |||||||||||||
Medical condition: Pemphigus: Pemphigus Vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004253-24 | Sponsor Protocol Number: CLNP023B12001B | Start Date*: 2019-08-28 |
Sponsor Name:Novartis Pharma AG | ||
Full Title: An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy | ||
Medical condition: C3 Glomerulopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) IT (Ongoing) FR (Ongoing) ES (Ongoing) DE (Ongoing) GR (Ongoing) NL (Ongoing) CZ (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.